The results showed that FXYD6 was significantly associated withHCC, and FXYD6 mRNA and protein were upregulated in HCC compared with normal livertissue and HBV-related cirrhosis, indicating that FXYD6 may be a new biomarker andtherapeutic target for HCC. This evidence concerns the gene FXYD6 and Cirrhosis.